Use of gonadotrophin releasing hormone (GnRH) antagonist (Cetrotide) during ovarian stimulation for in-vitro fertilization treatment: Multiple doses and single dose

Journal of Obstetrics and Gynaecology Research

Volumn 27, Issue 5, 2001, Pages 261-265

  Ng, E H Y ^a   Ho, P C ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

GnRH antagonist; IVF; Multiple doses; Single dose

Indexed keywords

CETRORELIX; CHORIONIC GONADOTROPIN; ESTRADIOL; FOLLITROPIN; GONADORELIN; GONADORELIN ANTAGONIST; LUTEINIZING HORMONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG USE; EMBRYO; EMBRYO TRANSFER; EXPERIENCE; FEMALE; FERTILIZATION IN VITRO; HORMONE ACTION; HORMONE INHIBITION; HUMAN; HUMAN CELL; INFERTILITY; LUTEINIZING HORMONE RELEASE; MULTICENTER STUDY; OOCYTE TRANSPORT; OVULATION INDUCTION; PROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0035194984     PISSN: 13418076     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2001.tb01267.x     Document Type: Article

References (12)

1. The routine use of gonadotropin releasing hormone agonists prior to in-vitro fertilization and gamete intrafallopian transfer: A meta-analysis of randomized controlled trials
2. Analogs of LHRH: The present and the future
3. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation
4. Scheduled administration of a gonadotrophin-releasing hormone antagonist (Cetrorelix) on day 8 of in-vitro fertilization cycles: A pilot study
5. Comparison of different doses of gonadotrophin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation
6. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon)
7. Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist Cetrorelix according to the multiple dose protocol: A prospective uncontrolled phase III study
8. High serum oestradiol levels in fresh IVF cycles do not impair implantation and pregnancy rates in subsequent FET cycles
9. Comparison of intermittent and continuous use of a gonadotrophin-releasing hormone antagonist (Nal-Glu) in in vitro fertilization cycles: A preliminary report
10. Prevention of premature luteinizing hormone and progesterone rise with a gonadotrophin-releasing hormone antagonist, Nal-glu, in controlled ovarian hyperstimulation
11. The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: A dose finding study of 3 versus 2 mg
12. Ovarian stimulation with HMG: Results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin